Skip to main content

Table 3 Median densities of various immune marker–expressing cells in NSCLCs from patients who received neoadjuvant chemotherapy (NCT) or did not receive NCT (non-NCT), by tumor histology (N = 112)

From: Effect of neoadjuvant chemotherapy on the immune microenvironment in non–small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches

Markers ADC (n = 64) P a SCC (n = 51) P a
non-NCT NCT non-NCT NCT
Median Cell Density (cells/mm2) Median Cell Density (cells/mm2)
Panel 1
 MCs (AE1/AE3+) 3135.42 3043.84 0.841 4125.37 3641.55 0.554
 MCs PD-L1+ 13.45 362.92 0.007 317.91 944.99 0.593
 CD3+ 916.14 1406.72 0.133 811.47 1825.85 0.070
 CD3 + CD4+ 671.49 997.47 0.170 650.63 1360.68 0.072
 CD3 + CD8+ 157.39 212.85 0.647 155.34 358.93 0.842
 CD68+ 298.80 591.42 0.430 321.12 705.60 0.040
 CD68 + PD-L1+ 196.71 222.96 0.600 172.72 357.54 0.090
Panel 2
 MCs (AE1/AE3+) 3134.08 2596.71 0.299 4528.99 3703.28 0.352
 CD45RO+ 623.31 595.51 0.484 723.46 1356.35 < 0.001
 CD45RO + CD57 + granzyme B− 240.95 332.13 0.008 118.68 395.21 0.013
 CD45RO + PD1+ 170.47 243.04 0.016 112.40 380.26 0.007
 CD45RO + FOXP3+ 7.17 7.17 0.448 4.18 9.56 0.073
 CD57 + granzyme B+ CD45RO− 4.26 40.65 < 0.001 9.86 9.86 0.925
 PD-1+ 426.90 718.68 0.014 273.84 1314.49 < 0.001
  1. ADC adenocarcinoma, SCC squamous cell carcinoma, MC malignant cells
  2. aMann Whitney U test